GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹10 Cr | ₹21 Cr | ₹16 Cr | ₹22 Cr | ₹13 Cr |
What is the latest Contingent Liabilities ratio of GLAND PHARMA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹10 Cr |
| Mar2025 | ₹21 Cr |
| Mar2024 | ₹16 Cr |
| Mar2023 | ₹22 Cr |
| Mar2022 | ₹13 Cr |
How is Contingent Liabilities of GLAND PHARMA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹10 Cr | -52.68 | |
| Mar2025 | ₹21 Cr | 37.24 | |
| Mar2024 | ₹16 Cr | -29.41 | |
| Mar2023 | ₹22 Cr | 72.94 | |
| Mar2022 | ₹13 Cr | - | |
Compare Contingent Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹47,619.8 Cr | 3% | 14.8% | 46.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹460,696.0 Cr | 0.5% | -4% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,063.0 Cr | 9.1% | 18.2% | 47.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,515.0 Cr | 3.6% | 3.4% | 36.4% | Stock Analytics | |
| CIPLA | ₹114,554.0 Cr | -1.2% | -3.3% | -10.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,308.6 Cr | -1.4% | 2.9% | -8% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 3% |
14.8% |
46.7% |
| SENSEX | -0.4% |
-0.5% |
-5.8% |
You may also like the below Video Courses